Cargando…
Further insight into AE37 peptide vaccination in prostate cancer
Autores principales: | Anastasopoulou, Eleftheria A, Voutsas, Ioannis F |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Future Science Ltd
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583690/ https://www.ncbi.nlm.nih.gov/pubmed/28883993 http://dx.doi.org/10.4155/fsoa-2017-0005 |
Ejemplares similares
-
Unraveling the role of preexisting immunity in prostate cancer patients vaccinated with a HER-2/neu hybrid peptide
por: Voutsas, Ioannis F., et al.
Publicado: (2016) -
DRB1*11 allele expression and HER2 pre-existing immunity may predict benefit in breast cancer patients vaccinated with the HER2 modified AE37 peptide vaccine
por: Anastasopoulou, Eleftheria A, et al.
Publicado: (2015) -
Prospective, randomized, single-blinded, multi-center phase II trial of two HER2 peptide vaccines, GP2 and AE37, in breast cancer patients to prevent recurrence
por: Brown, Tommy A., et al.
Publicado: (2020) -
Risk of selection bias in randomized trials: further insight
por: Berger, Vance W.
Publicado: (2016) -
Preparedness for further boosting coronavirus disease 2019 vaccines
por: Lim, So Yun, et al.
Publicado: (2022)